ArticleInterventional pain medicine2022
Clinical and radiological predictors of response to lumbar transforaminal epidural steroid injection at 3 months: A retrospective study.
Article in Interventional pain medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparing the clinical efficacy of preganglionic and preganglionic plus ganglionic transforaminal epidural steroid injections for lumbosacral radicular pain.Neurosciences (Riyadh, Saudi Arabia) · 2025Trial
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transforaminal epidural steroid injection (TFESI) is commonly used to relieve pain due to intervertebral disc displacements (IDD). Poorly defined selection criteria lead to post procedure dissatisfaction among patients. We aimed to find clinical and magnetic resonance imaging (MRI) predictors for pain relief at 3 months following a TFESI. Poorly defined selection criteria lead to post procedure dissatisfaction among patients. Methods: A retrospective study of 116 patients who had undergone TFESI. Predictors used were - age, duration of symptoms, body mass index, neuropathic character of pain, dermatomal distribution of pain, claudication distance, response to anti-neuropathic medication and extent of nerve root compromise in MRI as per Pfirmann criteria. A relief of 50% or more at the end of 3 months was considered the criterion for significant pain relief from TFESI. Results: At 3 months, 72% (84/116) had significant pain relief. Dermatomal distribution of pain (73%) and neurogenic claudication (71%) were the most prevalent clinical features. Dermatomal distribution of leg pain, responsiveness to anti-neuropathic medications and a Pfirmann grade 2/3 in MRI were the most important predictors with an odds ratio (OR) of 12.1, Conclusions: If a patient has leg pain which is dermatomal in distribution, responds to anti-neuropathic medications and has Pfirmann grade 2/3 in MRI, then chances of more than 50% relief persisting at 3 months after TFESI are significantly better.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.